Literature DB >> 29209647

Targeting RAS - will GPR31 deliver us a new path forward?

Nicole Fehrenbacher1, Mark R Philips1.   

Abstract

Effective anti-rat sarcoma viral oncogene (RAS) therapies have remained the holy grail of cancer treatment. Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) sustains tumorigenesis when linked to the plasma membrane (PM). The G protein-coupled receptor 31 (GPR31) is now identified to mediate KRAS membrane association and is crucial for proliferation, survival and macropinocytosis of KRAS-dependent cancer cells, suggesting that GPR31 is a druggable target for anti-RAS therapy.

Entities:  

Keywords:  Cancer; G-protein coupled receptor 31; GPR31; KRAS; RAS; anti-RAS therapy; cancer therapy

Year:  2017        PMID： 29209647      PMCID： PMC5706936          DOI： 10.1080/23723556.2017.1359228

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane.

Authors:  J F Hancock; H Paterson; C J Marshall
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

Review 2.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 3.  Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

Review 4.  Drugging RAS: Know the enemy.

Authors:  Bjoern Papke; Channing J Der
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

5.  12-HETER1/GPR31, a high-affinity 12(S)-hydroxyeicosatetraenoic acid receptor, is significantly up-regulated in prostate cancer and plays a critical role in prostate cancer progression.

Authors:  Kenneth V Honn; Yande Guo; Yinlong Cai; Menq-Jer Lee; Gregory Dyson; Wenliang Zhang; Stephanie C Tucker
Journal:  FASEB J       Date:  2016-03-10       Impact factor: 5.191

Review 6.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

7.  The G protein-coupled receptor GPR31 promotes membrane association of KRAS.

Authors:  Nicole Fehrenbacher; Israel Tojal da Silva; Craig Ramirez; Yong Zhou; Kwang-Jin Cho; Shafi Kuchay; Jie Shi; Susan Thomas; Michele Pagano; John F Hancock; Dafna Bar-Sagi; Mark R Philips
Journal:  J Cell Biol       Date:  2017-06-15       Impact factor: 10.539

Review 8.  Discovery and clinical introduction of first-in-class imipridone ONC201.

Authors:  Joshua E Allen; C Leah B Kline; Varun V Prabhu; Jessica Wagner; Jo Ishizawa; Neel Madhukar; Avital Lev; Marie Baumeister; Lanlan Zhou; Amriti Lulla; Martin Stogniew; Lee Schalop; Cyril Benes; Howard L Kaufman; Richard S Pottorf; B Rao Nallaganchu; Gary L Olson; Fahd Al-Mulla; Madeleine Duvic; Gen Sheng Wu; David T Dicker; Mala K Talekar; Bora Lim; Olivier Elemento; Wolfgang Oster; Joseph Bertino; Keith Flaherty; Michael L Wang; Gautam Borthakur; Michael Andreeff; Mark Stein; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2016-11-08

9.  Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.

Authors:  Cosimo Commisso; Shawn M Davidson; Rengin G Soydaner-Azeloglu; Seth J Parker; Jurre J Kamphorst; Sean Hackett; Elda Grabocka; Michel Nofal; Jeffrey A Drebin; Craig B Thompson; Joshua D Rabinowitz; Christian M Metallo; Matthew G Vander Heiden; Dafna Bar-Sagi
Journal:  Nature       Date:  2013-05-12       Impact factor: 49.962
  9 in total
  1 in total

1.  Telomere length correlates with subtelomeric DNA methylation in long-term mindfulness practitioners.

Authors:  Maite Mendioroz; Marta Puebla-Guedea; Jesús Montero-Marín; Amaya Urdánoz-Casado; Idoia Blanco-Luquin; Miren Roldán; Alberto Labarga; Javier García-Campayo
Journal:  Sci Rep       Date:  2020-03-12       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.